# Junta clínica — PT-pseudo_1185f6a68df0 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_1185f6a68df0",
  "pid": "PT-pseudo_1185f6a68df0",
  "task": 1,
  "psa": 7.0,
  "age": 63,
  "months": 2,
  "pirads": "5",
  "psad": 0.329,
  "psav": 1.09,
  "psap": 5.5,
  "vol": 21.27,
  "dre": "Normal",
  "bx": "None",
  "cspca": 0.8321669,
  "medhx": "Atrial fibrillation",
  "meds": "apixaban, metoprolol",
  "notes": "PSA 7 ng/mL. PI-RADS 5. PSAD 0.33. Prostate volume 21 mL. csPCa 0.83.",
  "pmhx": [
    "Atrial fibrillation"
  ],
  "allergies": [],
  "vitals": {
    "weight": "101 kg",
    "height": "179 cm",
    "bmi": "31.5",
    "bp": "100/66 mmHg",
    "hr": "72 bpm",
    "smoking": "Ex-smoker (22 pack-yr, quit 2021)",
    "last_dental": "6 mo ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "22 Feb 2025",
  "enc_ref": "Dr. P. van Dijk (GP)",
  "enc_type": "Follow-up - PSA + MRI",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Escalating prostate-specific antigen measurements across a two-year span prompted a recent multiparametric magnetic resonance imaging study."
    },
    {
      "s": "History",
      "t": "At sixty-three years of age, this retired mechanical engineer first entered clinical evaluation in early 2023 due to a PSA elevation, which has since steadily ascended to 7.0 ng/mL. His urological documentation indicates a prior biopsy bucket of None. Lower urinary tract complaints remain minimal, characterized by slight hesitancy and a modest increase in nocturia, yielding an IPSS score of 7. He explicitly denies hematuria or pelvic discomfort. Physical activity persists through cycling roughly 30 kilometres three times weekly, although advancing joint stiffness necessitates a walking frame for extended distances. He shares his home with his wife, while their grown daughter handles administrative correspondence. His clinical background includes atrial fibrillation, managed with apixaban and metoprolol. A substantial smoking history of 22 pack-years was successfully abandoned in 2021. Aside from receiving a standard influenza vaccination last week and maintaining stable blood pressure readings, he reports feeling generally well, with no complaints of unexplained fatigue or weight reduction."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: smooth and uniformly firm; mobility: unrestricted; asymmetry: absent. General inspection reveals a well-nourished individual in no acute distress. Vital signs demonstrate a regular heart rate of 72 beats per minute alongside a blood pressure of 100/66 mmHg. Peripheral pulses remain palpable, and there is no clinical evidence of peripheral oedema or lymphadenopathy."
    }
  ],
  "occupation": "retired mechanical engineer",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Adult daughter (primary contact)",
  "recent_other": [
    "GP practice nurse — flu vaccination"
  ],
  "alcohol": "5 units / week",
  "exercise": "Cycling 3x/week, ~30 km",
  "ipss": "IPSS score: 7/35 (mild LUTS)",
  "admin": "Mobility limitation (frame); ground-floor consult room preferred.",
  "mri_hospital": "Maastricht UMC+",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_1185f6a68df0
Task: 1

Encounter: Urology - outpatient on 22 Feb 2025.
Referrer: Dr. P. van Dijk (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 63-year-old male
  - PSA: 7.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.329 ng/mL²
  - PSA velocity: 1.09 ng/mL/yr
  - Prior PSA: 5.5 ng/mL
  - Prostate volume: 21.27 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8321669 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Atrial fibrillation
  - Problem list / PMHx: Atrial fibrillation
  - Current medication: apixaban, metoprolol
  - Allergies: NKA
  - Additional notes: PSA 7 ng/mL. PI-RADS 5. PSAD 0.33. Prostate volume 21 mL. csPCa 0.83.

Vitals: weight 101 kg, height 179 cm, BMI 31.5, BP 100/66 mmHg, HR 72 bpm. Smoking: Ex-smoker (22 pack-yr, quit 2021).

Chief complaint: Escalating prostate-specific antigen measurements across a two-year span prompted a recent multiparametric magnetic resonance imaging study.

History: At sixty-three years of age, this retired mechanical engineer first entered clinical evaluation in early 2023 due to a PSA elevation, which has since steadily ascended to 7.0 ng/mL. His urological documentation indicates a prior biopsy bucket of None. Lower urinary tract complaints remain minimal, characterized by slight hesitancy and a modest increase in nocturia, yielding an IPSS score of 7. He explicitly denies hematuria or pelvic discomfort. Physical activity persists through cycling roughly 30 kilometres three times weekly, although advancing joint stiffness necessitates a walking frame for extended distances. He shares his home with his wife, while their grown daughter handles administrative correspondence. His clinical background includes atrial fibrillation, managed with apixaban and metoprolol. A substantial smoking history of 22 pack-years was successfully abandoned in 2021. Aside from receiving a standard influenza vaccination last week and maintaining stable blood pressure readings, he reports feeling generally well, with no complaints of unexplained fatigue or weight reduction.

Physical examination: DRE — texture: smooth and uniformly firm; mobility: unrestricted; asymmetry: absent. General inspection reveals a well-nourished individual in no acute distress. Vital signs demonstrate a regular heart rate of 72 beats per minute alongside a blood pressure of 100/66 mmHg. Peripheral pulses remain palpable, and there is no clinical evidence of peripheral oedema or lymphadenopathy.

Patient info: retired mechanical engineer; Married; Lives with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 5 units / week; exercise Cycling 3x/week, ~30 km; IPSS score: 7/35 (mild LUTS).

Recent other appointments: GP practice nurse — flu vaccination.
Admin: Mobility limitation (frame); ground-floor consult room preferred.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.88
  uncertainty  +/- 0.06 epistemic (95% band 0.77-0.99); among patients I cannot tell apart the outcome was 0.54 of 1.00 mixed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: never biopsied. My criterion answers BIOPSY.

The criterion: sample when the mpMRI shows a PI-RADS 3 or higher lesion; defer at PI-RADS 1-2. In the labelled series this criterion matched the reading urologist in 24 of 24 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 24 labelled men in this same situation (None prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.00 — IDENTICAL PANEL: this is the same case, already in the labelled series: PI-RADS 5, PSA 7.0, PSAD 0.329, age 63, DRE Normal -> BIOPSY (clear). He wrote: "P5 in a man with rapid increasing PSA"
  2. distance 0.49: PI-RADS 5, PSA 9.0, PSAD 0.409, age 65, DRE Normal -> BIOPSY (clear). He wrote: "P5 in a man with high PSA"
  3. distance 0.79: PI-RADS 5, PSA 5.9, PSAD 0.199, age 60, DRE Normal -> BIOPSY (clear). He wrote: "PIRADS 5 in a 60 year old man"

PRECEDENT: BIOPSY. The nearest precedent is this very patient, so the library returns what the reading urologist actually did with him. That is a record, not a judgement; out of sample this expert is worth only what the distance is worth.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. This patient is in the labelled series, so what follows is the reading urologist's own trace for him, not a prediction.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: pirads=decisive, vol=noted, dre=noted, bx=noted, comorbidity=noted, age=important, fh=noted, psa=important, psad=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines link PI-RADS scores to the indication for biopsy, stating that a PI-RADS threshold of $\ge 3$ is used to trigger biopsy. The guideline also suggests that MRI-directed US-guided prostate biopsy is now the standard of care.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is not decisive because the guideline requires a PI-RADS score of 3 or higher, and the cohort criterion specifically matched the reading urologist in 24 of 24 cases in this exact situation. The precedent shows that the reading urologist proceeded with a biopsy in similar cases, which is what the library reflects.

WHAT WE STILL NEED
The guideline requires the PI-RADS score, which is known to be 5, which is above the threshold of 3. The panel also shows a prior biopsy status of "None," which is a fact that the guideline makes decisive regarding the need for a biopsy.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case strongly suggests proceeding with a biopsy based on the PI-RADS score and the guideline threshold, but we must confirm the specific details from the opened documents.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone of the PI-RADS 5 lesion?
  psa_trend (get_psa_trend) -> What is the trend of the serial PSA values?
  previous_notes (get_previous_notes) -> What is the management context regarding the prior biopsy status, surveillance protocol, and planned treatment?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the Gleason or ISUP grade from the previous notes?
  Q2. Is there a surveillance protocol in place, and if so, is a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The lesion size and zone of the PI-RADS 5 lesion is "approximately 12 x 9 mm within the left peripheral zone at the mid-gland level."
psa_trend
The trend of the serial PSA values is [{"date": "Mar 2023", "val": 1.3}, {"date": "Feb 2024", "val": 3.0}, {"date": "Feb 2025", "val": 7.0}].
previous_notes
The management context regarding the prior biopsy status, surveillance protocol, and planned treatment is "Prior biopsy: None. Surveillance: not recorded. Treatment: none recorded."

WHAT I DID NOT OPEN
family-history anamnesis because the decision hinges on the imaging and PSA trend/history.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 5 lesion located in the left peripheral zone (mid-gland), spanning approximately 12 x 9 mm.
PSA trend shows a rapid increase from 1.3 ng/mL in Mar 2023 to 7.0 ng/mL in Feb 2025.
BIOPSY AGAINST sampling this patient now
Surveillance protocol is not recorded.

WHERE THIS LEANS
The PI-RADS 5 finding, combined with the rapid PSA increase, strongly supports proceeding with a biopsy as per the EAU guideline threshold.
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 7.00 ng/mL over 3 points spanning 23 months; velocity +2.99 ng/mL per year; doubling time about 9 months.
PROJECTION at 6 months: 10.0 ng/mL, conformal 95% band 2.9-34.8.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.86
  uncertainty  +/- 0.05 epistemic (95% band 0.76-0.96), of which 0.01 comes from values that had to be imputed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 89% of the time over the 37 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.88  ('firm' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.86  ('firm' tier, fusion_nolab)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=1.00  (identical panel in the series)
  EXPERT-COHORT      BIOPSY  (rule pirads_ge_3)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: identical precedent in the labelled series — carried by EXPERT-LIBRARY.
PANEL ANSWER: BIOPSY. The labelled series contains this exact panel; the library returns the reading urologist's own decision for it. Out of sample this rung never fires.

Confidence the trace model expects here: clear. Weights it expects: pirads=decisive, vol=noted, dre=noted, bx=noted, comorbidity=noted, age=important, fh=noted, psa=important, psad=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened—radiology_report, psa_trend, and previous_notes—have addressed the moderator's questions to the extent possible. The registrar retrieved information regarding the PI-RADS 5 lesion size and zone from the radiology report, the serial PSA trend from the PSA trend document, and the management context regarding prior biopsy status and surveillance from the previous notes.

ALIGNMENT WITH THE PANEL
The retrieved evidence strongly aligns with the PANEL-PROTOCOL's answer of BIOPSY. Specifically, the radiology report confirmed a PI-RADS 5 lesion, and the previous notes explicitly stated "Prior biopsy: None. Surveillance: not recorded," which supports the need for intervention.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the Gleason or ISUP grade from the previous notes? This information was not retrieved by the registrar.
Q2. Is there a surveillance protocol in place, and if so, is a confirmatory biopsy due? The previous notes state surveillance is "not recorded," leaving this question unanswered by the retrieved documents.

WHAT CARRIES WEIGHT, AND WHY
The PI-RADS score of 5 is the most critical variable, as it directly triggers the EAU guideline threshold for biopsy. The rapid PSA trend, showing a velocity of +2.99 ng/mL per year, further emphasizes the need for action. The lack of a recorded surveillance protocol is also highly relevant.

MY SUGGESTION TO THE CHAIR
Based on the PI-RADS 5 finding and the rapid PSA progression, I suggest proceeding with a biopsy. This should be done firmly, as the guideline threshold has been met and the necessary context regarding surveillance is missing from the record.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the PI-RADS score of 5 meets the EAU guideline threshold for intervention, and the rapid PSA trend, showing a velocity of +2.99 ng/mL per year, further supports this action. The evidence converged on biopsy due to the PI-RADS 5 finding and the lack of a recorded surveillance protocol in the previous notes. The room resolved the decision because the PI-RADS 5 finding, combined with the rapid PSA progression, strongly supported proceeding with a biopsy.

What carried weight: pirads=decisive, vol=noted, bx=noted, comorbidity=noted, age=important, psa=important, psad=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
